Form 4: XOMA Corp Director Heather L. Franklin Acquires Stock Options

Heather L. Franklin, a director of XOMA Corp, acquired 9,763 non-qualified share options on May 15, 2024.

Summary

• On May 15, 2024, Heather L. Franklin, a director of XOMA Corporation, acquired 9,763 non-qualified share options.
• The exercise price of these options is $24.71.
• The options vest in equal monthly installments over a 12-month period following the grant date, with the final installment occurring on the earlier of the next annual meeting or the first anniversary of the grant date, contingent upon continued service to the company.
• The options expire on May 15, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, neither particularly positive nor negative.

Positives

• The acquisition of share options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech industry.
• The vesting schedule of 12 months is fairly standard.
• Comparable companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation strategy.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates